GLP‑1 drugs drive major shift in fitness industry and spark calls for integrated exercise programs

Management‑consulting firms including PwC and McKinsey predict that rapid adoption of GLP‑1 weight‑loss drugs will fundamentally reshape the fitness and wellness sector. By 2025 household penetration in the United States is expected to rise from 9 % to 20 %, prompting higher gym membership spend, a move toward strength‑training and boutique studios, and a demand for hybrid, data‑rich fitness ecosystems.

A multinational white paper from the Health & Fitness Association, developed with fitness federations in the United States, Australia, Canada, New Zealand and the United Kingdom, finds that pairing structured exercise with GLP‑1 therapy dramatically improves long‑term health outcomes and generates substantial economic returns. Over a ten‑year horizon the combined approach is projected to create US $120 billion in value in the United States, A$182 million in Australia, C$3.5 billion in Canada, NZ$51 million in New Zealand and £2.7 billion in the United Kingdom, with returns rising sharply over thirty years. The report urges policymakers, payers and health systems to recognize structured exercise as an essential component of obesity care and to establish referral pathways to qualified fitness professionals.